Natalya L Bogdanova

Dr. Natalya L Bogdanova

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
NGNadezhda Gumanova
Nadezhda Gumanova
DVDmitry K. Vasilyev
Dmitry K. Vasilyev
NBNatalya L Bogdanova
Natalya L Bogdanova
YHYaroslav I. Havrichenko
Yaroslav I. Havrichenko
AKAlexander Y Kots
Alexander Y Kots
VMVictoria A. Metelskaya
Victoria A. Metelskaya

25 July 2023 in Viruses
Verified
Journal Article
Open access
PDF file
NGNadezhda Gumanova
Nadezhda Gumanova
AGAlexander Gorshkov
Alexander Gorshkov
NBNatalya L Bogdanova
Natalya L Bogdanova
AKAndrei I. Korolev
Andrei I. Korolev
Background: The manifestations, severity, and mortality of COVID-19 are considered to be associated with the changes in various hematological parameters and in immunity. Associations of immunoglobulin G antibodies against severe acute respiratory syndrome-linked coronavirus (IgG-SARS)-positive status with cardiac function and hematological and biochemical parameters in apparently health subjects are poorly understood. Methods: The present cross-sectional study included 307 healthy volunteers (24–69 years of age; 44.8 ± 8.6 years; 80.4% men) and was initiated in 2019 before the COVID-19 pandemic. COVID-19 episodes were confirmed by detection of IgG-SARS against SARS-CoV-2 S1 RBD to reveal 70 IgG-SARS-positive and 237 negative participants. Numerous ultrasound characteristics were assessed by echocardiography, and 15 hematological and biochemical parameters were assayed in the blood. Descriptive and comparative analysis was based on the IgG-SARS status of the participants. Results: The left ventricular mass index, mitral ratio of peak early to late diastolic filling velocity or flow velocity across the mitral valve, and deceleration time of early mitral inflow were decreased (p < 0.05) in IgG-SARS-positive participants versus those in IgG-SARS-negative participants according to multivariate logistic regression analysis. Erythrocyte sedimentation rate and platelet count were slightly increased, and blood hemoglobin was decreased in IgG-SARS-positive participants compared with those in IgG-SARS-negative participants. Conclusions: LV filling, inflammation, blood coagulation, and hemoglobin appear to be influenced by COVID-19 infection in healthy participants. Our observations contribute to the definition of vulnerabilities in the apparently healthy subjects with long COVID-19. These vulnerabilities may be more severe in patients with certain chronic diseases.

10 April 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
NGNadezhda Gumanova
Nadezhda Gumanova
AGAlexander Gorshkov
Alexander Gorshkov
NBNatalya L Bogdanova
Natalya L Bogdanova
AKAndrew I. Korolev
Andrew I. Korolev
ODOksana M. Drapkina
Oksana M. Drapkina
Background: Longitudinal surveys to monitor the seroprevalence are required to support efforts for assessment of the levels of endemic stability in certain countries. We investigated seroprevalence of anti-SARS-CoV-2-S1 receptor-binding domain (RBD)-specific antibodies in the serum samples in 2011–2021, including a cohort study of 2019–2021, to evaluate the vaccination and anti-IgG-SARS-CoV-2–S1 RBD-positive statuses to assess the resistance and severity of COVID-19. Materials and Methods: Anti-SARS-CoV-2-S1 RBD-specific antibodies were assayed in the serum samples (N = 565) randomly selected from various cohorts previously recruited from 2011 to 2021 from the city of Moscow and Moscow Region. Among them there were the participants (N = 310) recruited in 2019–2021 with an endpoint of 30 October 2021 when these participants were interviewed over phone with relevant questionnaire. Results: Obtained data indicated a percentage of 3–6% of SARS-CoV-2-S1 RBD-specific antibodies detected in participants recruited in 2011–2019. The percentage of SARS-CoV-2-S1 RBD-specific antibodies was increased to 16.5% in 2020 and to 46% in 2021. The vaccination rate of 238 respondents of this cohort was 58% from August 2020 to October 2021. In total, 12% of respondents were hospitalized. The morbidity rate in the subgroup of anti-SARS-CoV-2-S1 RBD-positive respondents was 5.4-fold higher than that in the subgroup of vaccinated respondents. Conclusions: A small percentage of SARS-CoV-2-S1 RBD-specific antibodies detected in 2011–2019 indicated possible spreading of coronaviruses during the pre-pandemic period. Collective immunity in Moscow and the Moscow region was able to reach 69% from August 2020 to October 2021 if this rate is added to the rate of not vaccinated SARS-CoV-2-S1 RBD-positive subjects.

16 July 2021 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
MZM. V. Zhatkina
M. V. Zhatkina
VMVictoria A Metelskaya
Victoria A Metelskaya
NGN. E. Gavrilova
N. E. Gavrilova
Elena YarovayaElena Yarovaya
Elena Yarovaya
IMIuliia Makarova
Iuliia Makarova
ODOxana M. Drapkina
Oxana M. Drapkina
Aim. To assess the individual and complex prognostic value of various blood biochemical parameters (biomarkers) in the non-invasive diagnosis of coronary artery (CA) atherosclerosis.Material and methods. The study included 216 patients (men, 115; women, 101) aged 24 to 87 years (mean age, 61,5±10,7 years), who underwent indicated coronary angiography. All patients underwent a biochemical blood tests to determine the parameters of lipid, carbohydrate and nitrogen metabolism, the hemostatic system, inflammatory markers, as well as the creatinine level as an indicator of renal function.Results. Analysis revealed biomarkers, the deviations in the level of which contribute to the diagnosis and determination of the coronary involvement. These biomarkers include glucose, creatinine, C-reactive protein, and adiponectin. Using these biochemical parameters, a multivariate model (MVM) was constructed, which was significant for the diagnosis of coronary atherosclerosis and determination of its severity. With the help of ROC-analysis, the cutoff point of MVM of 2 was found. MVM >2 with a sensitivity of 72% indicate CA atherosclerosis of any severity, as well as with a specificity of 62,5%, it can be ruled out. Using MVM data and a cutoff point of 2, a binary logistic regression model was built, according to which, with a MVM >2, the odds for detecting CA atherosclerosis of any degree is 2,1 times higher (95% confidence interval (CI), 1,2-3,8; p=0,010), severe CA — 4,7 times (95% CI, 1,9-12,0; p=0,001) compared with individuals with MVM ≤2, who have 2,8 times (95% CI, 1,4-4,9; p=0,002) a higher chance of detecting intact CAs.Conclusion. Thus, the total MVM score of 0-2 indicates the absence of coronary atherosclerosis, while 3-4 points -CA atherosclerosis of any severity.

8 January 2022 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
VMVictoria A Metelskaya
Victoria A Metelskaya
MZM. V. Zhatkina
M. V. Zhatkina
NGN. E. Gavrilova
N. E. Gavrilova
Elena YarovayaElena Yarovaya
Elena Yarovaya
NBNatalya L Bogdanova
Natalya L Bogdanova
ODOxana M. Drapkina
Oxana M. Drapkina
Aim. To identify and characterize the associations of the presence and severity of atherosclerosis of various localization with the blood level of biochemical parameters, as well as to assess the potential of their use as markers of metabolic disorders with increased atherogenic potential.Material and methods. The study included 216 patients (men, 53%) aged 24-87 years (mean age, 61,5±10,73 years). All patients underwent coronary angiography, carotid (CA) and femoral arterial (FA) duplex ultrasound to assess the presence and severity of atherosclerosis. In blood serum/plasma, biochemical parameters were analyzed using standard methods.Results. Based on the analysis of circulating biomarker profile, diagnostic complexes have been established that allow assessing atherosclerosis of different localization. According to the data obtained, the determinants of coronary and CA atherosclerosis are endothelial dysfunction (concentration of nitric oxide metabolites <36,0 μmol/L) and an increased level of creatinine (≥73,0 μmol/L). The specific markers associated with severe atherosclerosis of coronary and FAs (but not CA) were low high-density lipoprotein cholesterol (≤1,0/1,2 μmol/L for male/ female, respectively) and an increased C-reactive protein level (≥1,0 mg/l). Severe peripheral atherosclerosis (CA and FA involvement) was associated with hyperglycemia (glucose ≥6,1 μmol/L), while severe FA atherosclerosis — with hyperinsulinemia (insulin ≥14,0 μU/ml).Conclusion. The analysis of associations of circulating biochemical parameters with atherosclerosis localization and severity revealed a number of metabolic markers associated with the increased atherogenic potential. It is possible to distinguish both universal parameters that are associated with atherosclerosis, regardless of its localization and/or severity, and specific biomarkers that characterize either the localization or the severity of atherosclerosis, or both.

22 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NGNadezhda Gumanova
Nadezhda Gumanova
DVDmitry K. Vasilyev
Dmitry K. Vasilyev
NBNatalya L Bogdanova
Natalya L Bogdanova
ODOksana M. Drapkina
Oksana M. Drapkina
Background: Placental cadherin (CDH3) is an adhesion molecule expressed in many malignant tumors. The role of serum CDH3 in atherosclerosis is unclear. Methods: This 3-year follow-up study measured atherosclerosis and serum CDH3 in 218 angiography inpatients. Coronary stenosis was assessed as the Gensini score. The brachiocephalic and femoral plaques were quantified by ultrasound. Microarray serum profiling was conducted in selected samples. CDH3 in the serum was measured using an indirect ELISA. The odds ratio (OR), ROC analysis, and logistic regressions were used to evaluate the associations between CDH3 content, atherosclerotic lesions, and various serum biomarkers. Results: Serum CDH3 was associated with the severity of atherosclerosis and diastolic blood pressure. The levels of CDH3 were able to discriminate patients with total subclinical and hemodynamically significant atherosclerotic lesions in all circulation pools (coronary, brachiocephalic, and femoral). Elevated serum CDH3 appeared to be a risk factor for cardiovascular outcomes after 3-year follow up with OR = 1.81 (95% CI: 1.07–3.72; p = 0.022). Endothelin-1 and NOx were associated with the content of CDH3 in the serum, suggesting the involvement of certain signal transduction pathways that may participate in plaque formation. Conclusions: CDH3 was associated with cardiovascular outcomes adjusted for coronary plaque presence, indicating a role of CDH3 in plaque biology.